Cargando…
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ±...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481643/ https://www.ncbi.nlm.nih.gov/pubmed/26111974 http://dx.doi.org/10.1038/srep10202 |
_version_ | 1782378301166190592 |
---|---|
author | Song, Xiaoyan Jia, Hetang Jiang, Yuebo Wang, Liang Zhang, Yan Mu, Yiming Liu, Yu |
author_facet | Song, Xiaoyan Jia, Hetang Jiang, Yuebo Wang, Liang Zhang, Yan Mu, Yiming Liu, Yu |
author_sort | Song, Xiaoyan |
collection | PubMed |
description | This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m(2) (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [−0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (−40.16 [−51.50, −28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (−0.27 [−0.48, −0.07]; P = 0.009), plasminogen activator inhibitor-1 (−12.90 [−25.98, 0.18]; P=0.05), total cholesterol (−5.47 [−9.55, −1.39]; P = 0.009), LDL-cholesterol (−3.70 [−7.39, −0.00]; P = 0.05) and triglycerides (−16.44 [−25.64, −7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence. |
format | Online Article Text |
id | pubmed-4481643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44816432015-06-30 Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis Song, Xiaoyan Jia, Hetang Jiang, Yuebo Wang, Liang Zhang, Yan Mu, Yiming Liu, Yu Sci Rep Article This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m(2) (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [−0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (−40.16 [−51.50, −28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (−0.27 [−0.48, −0.07]; P = 0.009), plasminogen activator inhibitor-1 (−12.90 [−25.98, 0.18]; P=0.05), total cholesterol (−5.47 [−9.55, −1.39]; P = 0.009), LDL-cholesterol (−3.70 [−7.39, −0.00]; P = 0.05) and triglycerides (−16.44 [−25.64, −7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence. Nature Publishing Group 2015-06-26 /pmc/articles/PMC4481643/ /pubmed/26111974 http://dx.doi.org/10.1038/srep10202 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Song, Xiaoyan Jia, Hetang Jiang, Yuebo Wang, Liang Zhang, Yan Mu, Yiming Liu, Yu Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title_full | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title_fullStr | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title_full_unstemmed | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title_short | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
title_sort | anti-atherosclerotic effects of the glucagon-like peptide-1 (glp-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481643/ https://www.ncbi.nlm.nih.gov/pubmed/26111974 http://dx.doi.org/10.1038/srep10202 |
work_keys_str_mv | AT songxiaoyan antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT jiahetang antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT jiangyuebo antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT wangliang antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT zhangyan antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT muyiming antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis AT liuyu antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis |